# Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH

> **NCT03332940** · PHASE1 · TERMINATED · sponsor: **Navidea Biopharmaceuticals** · enrollment: 6 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis
- NASH - Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** Tc 99M Sulfur Colloid
- **DRUG:** Tc99m-tilmanocept

## Key facts

- **NCT ID:** NCT03332940
- **Lead sponsor:** Navidea Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-06
- **Primary completion:** 2019-03-10
- **Final completion:** 2019-03-10
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** No meaningful differences in the pattern of liver uptake were observed between Tc 99m tilmanocept and the comparator (Tc 99m sulfur colloid) after a review of the first six subjects.
- **Last updated:** 2024-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03332940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03332940, "Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03332940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*